Business
Half-year Report
Half-year Report.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2629D Scancell Holdings Plc 30 January 2018 \n\n30 January 2018\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nInterim Results for the six months ended 31 October 2017\n \nBlue chip collaborations validate ImmunoBody® and Moditope® platforms\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces its interim results for the six months ended 31 October 2017. \n \nHighlights:\n \n· Dr Cliff Holloway appointed as Chief Executive Officer during the period, succeeding Dr Richard Goodfellow from 10 January 2018 \n \n· £4.7m net proceeds raised in a placing of new ordinary shares in May 2017 \no Funds used to initiate the clinical development of Modi-1 and to continue to support the ImmunoBody® platform pipeline\n \n· Investigational New Drug application for SCIB1 Phase 2 checkpoint inhibitor combination study expected to be submitted in H1 2018, with patient enrolment planned to start H2 2018\n \n· Continued progress in the development of Modi-1, our lead product from the Moditope® platform\no Process development work underway for the manufacture of Modi-1 conjugated to an ultra-efficient adjuvant\no First-in-man clinical studies for triple negative breast cancer, ovarian cancer and sarcoma anticipated to commence in H1 2019 \n \n· Patent granted in Europe for Scancell's DNA ImmunoBody® technology; counterparts to this patent have already been granted in the US, Australia and Japan\n \n· Loss for the 6-month period of £2.02 million (2016: loss: £1.72 million)\n \n· Group cash balance at 31 October 2017 was £5.0 million (30 April 2017: £2.7 million) \n \n \nPost Period Highlights:\n \n· Collaboration with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer, expanding potential therapeutic utility of Moditope® to adoptive T cell therapy\n \n· Clinical development...